Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

被引：23

作者：

Koch, Kevin M. ^{[1
]}

Im, Young-Hyuck ^{[2
]}

Kim, Sung-Bae ^{[3
]}

Ribate, Ander Urruticoechea ^{[4
]}

Stephenson, Joe ^{[5
]}

Botbyl, Jeffrey ^{[6
]}

Cartee, Leanne ^{[7
]}

Holshouser, Jane ^{[8
]}

Ridgway, Derry ^{[7
]}

机构：

[1] GlaxoSmithKline, Clin Pharmacol Modeling & Simulat, Res Triangle Pk, NC USA

[2] Samsung Med Ctr, Seoul, South Korea

[3] Asan Med Ctr, Seoul, South Korea

[4] Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain

[5] Canc Ctr Carolinas, Greenville, SC USA

[6] Provonix LLC, Cincinnati, OH USA

[7] GlaxoSmithKline, Oncol Drug Dev, London, England

[8] ICON Clin Res, Dublin, Ireland

来源：

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2013年 / 2卷 / 04期

关键词：

esomeprazole; lapatinib; breast cancer; proton pump inhibitor; drug interaction;

D O I：

10.1002/cpdd.45

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aqueous solubility of lapatinib declines significantly at pH>4, suggesting that its bioavailability might be lowered by acid-reducing drugs. A study was therefore conducted to assess the effects of esomeprazole on lapatinib pharmacokinetics (PK). Women with metastatic human epidermal growth factor receptor 2 positive (HER2(+)) breast cancer were enrolled. Patients received 1,250 mg lapatinib once daily (QD) in the morning on Days 1-7 (Period 1) and Days 8-14 (Period 2) with 40 mg esomeprazole QD at bedtime 3 hours after dinner on Days 8-14. Lapatinib PK sampling occurred during the 24-hour steady-state dosing intervals on Day 7 (lapatinib alone) and Day 14 (lapatinib with esomeprazole). Esomeprazole treatment resulted in decreased lapatinib bioavailability (mean 26%, range 6-49%) that was inversely associated with patient age as a significant covariate.

引用

页码：336 / 341

页数：6

共 50 条

[41] Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer
Mutlu, Hasan
Buyukcelik, Abdullah
Akca, Zeki
Erden, Abdulsamet
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (01) : 72 - 73
[42] The Role of Lapatinib in the Preoperative Therapy of Breast Cancer
Hirsh, Rebecca L.
DeMichele, Angela
CURRENT ONCOLOGY REPORTS, 2012, 14 (01) : 44 - 47
[43] LONG-TERM CONTROL OF BRAIN METASTASES IN BREAST CANCER PATIENTS BY LAPATINIB
Tesarova, Petra
Sedlackova, Eva
Petrakova, Katarina
Palacova, Marketa
Grell, Peter
BREAST, 2011, 20 : S37 - S37
[44] Lapatinib and ixabepilone for the treatment of metastatic breast cancer
Halterman, Patti A.
PHARMACOTHERAPY, 2008, 28 (10): : 1255 - 1266
[45] Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
Rana, Punam
Sridhar, Srikala S.
BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2012, 6 : 67 - 77
[46] Lapatinib: new opportunities for management of breast cancer
Liao, Julia
Gallas, Michelle
Pegram, Mark
Slingerland, Joyce
BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 79 - 91
[47] The Role of Lapatinib in the Preoperative Therapy of Breast Cancer
Rebecca L. Hirsh
Angela DeMichele
Current Oncology Reports, 2012, 14 : 44 - 47
[48] Lapatinib plus capecitabine in breast cancer - Reply
Geyer, Charles E.
Forster, John
Cameron, David
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (14): : 1471 - 1472
[49] Population pharmacokinetics of esomeprazole in adult patients with gastroesophageal reflux disease
Li, J
Lind, T
Tzeng, T
Birmingham, B
Zhao, J
Andersson, T
Martin, P
Lundborg, P
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P92 - P92
[50] Lapatinib shows promise for inflammatory breast cancer
不详
CANCER BIOLOGY & THERAPY, 2007, 6 (01) : 8 - 8

← 1 2 3 4 5 →